Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MITF | O75030 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965768 | 1.00 | POLB (0.72) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2434452 | 0.98 | POLB (0.70) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| Tert-Butylbenzene SCHEMBL27728888 | 0.89 | POLB (0.59) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL5468019 | 0.87 | POLB (0.57) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL30421484 | 0.87 | POLB (0.61) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL398161 | 0.87 | POLB (0.61) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL1558956 | 0.85 | POLB (0.68) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL1887873 | 0.85 | NR4A2 (0.67) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL29848366 | 0.85 | NR4A2 (0.67) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL21437406 | 0.84 | POLB (1.00) | POLBNR4A2LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090498-A1 | TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES | ADIENNE PHARMA & BIOTECH SA (CH) | 2025-03-20 | — | — | US | claimed |
| CN-118854494-B | Preparation method of viscose-based carbon fiber material | 安徽弘昌新材料股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118854494-A | Preparation method of viscose-based carbon fiber material | 安徽弘昌新材料股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-115677560-B | Synthesis method of 1,2,3, 9-tetrahydro-9-methyl-4H-carbazole-4-one | 常州兰陵制药有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114656574-B | Preparation method of cellulose-indolyl antibacterial material | 陕西科技大学 | 2023-10-24 | — | — | CN | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | claimed |
| CN-116102487-A | Pleuromutilin derivative compound and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2023-05-12 | — | — | CN | claimed |
| CN-114702504-B | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2023-04-07 | — | — | CN | claimed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | claimed |
| CN-1468112-A | 5－HT4Use of receptor antagonists for the prevention or treatment of certain cardiovascular diseases | ������ʷ��˹����ʵ���ҹ�˾ | 2004-01-14 | — | — | CN | claimed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | claimed |
| EP-1311295-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | Laboratoire Glaxosmithkline S.A.S. (FR) | 2003-05-21 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | claimed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2002011766-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | LABORATOIRE GLAXOSMITHKLINE S.A.S. (FR) | 2002-02-14 | — | — | WO | claimed |
| WO-2001055109-A1 | AROMATIC AMIDES ACTING ON MELANOCORTIN RECEPTORS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
| CN-1083059-A | The indoles that 3-piperidine methyl carboxylicesters replaces | GLAXO GROUP LTD (GB) | 1994-03-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090498-A1 | TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES | CD274, PDCD1, ICOS | POLB 1018/4885NR4A2 2836/4885LMNA 4630/4885 |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | POLB 3656/4885NR4A2 1290/4885LMNA 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.